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Abstract
This work reports the synthesis of  a new, never before reported molecule, which is 2, 3-butanedione 
monoxime tertbutyl-thiosemicarbazone (BDMO-tBTSC), and its characterization by 1H NMR (Nu-
clear Magnetic Resonance spectroscopy), 13C NMR, and HSQC (Heteronuclear Single Quantum 
Coherence) NMR. Assignment of  the 1H signals was supported by 1H-15N HSQC, and is consis-
tent with our proposed structure.
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Introduction 
The organic compounds known as oximes have 
a long history and were first discovered and 
characterized in the 1880’s by chemist Victor 
Meyer in Germany (1). One of  the interesting 
chemical facets of  oximes is their ability to bind 
to transition metal ions (2). An example of  one 
of  these, dimethylglyoxime, or DMG, is used 
throughout the U.S. in freshman chemistry lab 
classes as a chelating agent for the Ni2+ ion (3). 
The demonstrative reaction of  the two chemi-
cals in water produces an immediate blood-red 
precipitate of  the Ni(DMG)2 complex.  
Of  interest to us is the class of  organic 
compounds known as thiosemicarbazones, 
which have generated many literature articles in 
recent years due to their biological properties. 
The biological properties of  thiosemicarbazone 
compounds have been well-documented in the 
literature for several decades, and include anti-
fungal and anti-bacterial agents, as well as 
many potential medicinal agents including 
anticancer agents (4)-(6). The most important 
of  these thiosemicarbazone compounds used 
today is the anti-cancer drug known as 
Triapine, which has been in Phase II clinical 
trials for several years (7)-(8). Triapine has been 
shown to be a potent ribonucleotide reductase 
inhibitor, and this ability is what makes it useful 
as an anti-cancer agent, since ribonucleotide 
reductase is an important enzyme absolutely 
essential for human DNA replication in mitotic 
cell division.
Our lab has been active in synthesizing and 
characterizing thiosemicarbazones, so the 
attempt was made by us to attach an oxime 
group to a thiosemicarbazone molecule using 
the following synthesis pathway, shown in 
Figure 1, which utilizes 2,3-butanedione
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monoxime as the primary starting material. We 
used 4-tertbutyl-3-thiosemicarbazide as the rea-
gent which couples at the ketone carbon via a 
typical condensation reaction (9).  
This work reports the synthesis of  a new 
molecule BDMO-tBTSC, and the NMR 
characterization of  this new compound in the 
hope of  providing a foundation for further 
research into promising members of  the 
oximethiosemicarbazone series.  
Acronyms 
BDMO = 2,3-butanedione monoxime 
tBTSC = 4-tertbutyl-3-thiosemicarbazide 
BDMO-tBTSC = 2,3-butanedione tertbutyl-
thiosemicarbazone 
NMR = Nuclear Magnetic Resonance 
HSQC = Heteronuclear Single Quantum Co-
herence 
Experimental Section 
The 4-tertbutyl-3-thiosemicarbazide (tBTSC), 
and 2,3-butanedione monoxime were all pur-
chased from the Sigma-Aldrich Chemical Com-
pany. The other reagents and solvents that were 
used in this research were purchased from the 
Sigma-Aldrich, ARCOS and Fisher chemical 
companies. All materials were reagent grade or 
better and were used without further 
purification. The 1H NMR spectra were 
obtained on a Bruker Ascend-500 Multi-
Nuclear NMR spectrometer.
Three different methods to synthesize 
the 2, 3-butanedione tertbutyl-
thiosemicarbazone molecule: 
1. A 50mL Erlenmeyer flask containing a 
magnetic stir bar was placed within the hood, 
and 1.004g (6.82 x 10-3 mol) of  4-tert-butyl-3-
thiosemicarbazide and 0.814g (6.82 x 10-3 mol) 
of  2, 3-butanedione monoxime were added to 
the flask, along with15 mL of  isopropanol as 
solvent. One drop of  concentrated H2SO4 was 
added to the reaction mixture to catalyze the 
reaction. The mixture was heated to 60oC and 
left to react overnight. The solution was 
concentrated to 5 ml of  solvent. At this time the 
product precipitated out of  solution as off-white 
crystals. The product was vacuum-filtered and 
thoroughly dried. The total yield of  product 
(BDMO-tBTSC) was 0.817g (3.55 x 10-3 mol, 
52.1% Yield). 
2. A 50-mL Erlenmeyer flask containing a 
magnetic stir bar was placed within the hood, 
and 1.013g (6.88 x 10-3 mol) of  4-tert-butyl-3-
thiosemicarbazide and 0.819g (6.88 x 10-3 mol) 
of  2,3-butandione monoxime were added to the 
flask,  along with 25 mL of  a solution consisting 
of  50% ethanol and 50% water as solvent. One 
drop of  concentrated H2SO4 was added to the 
reaction mixture to catalyze the reaction. The 
mixture was heated to 60oC and left to react 
overnight. The resulting white precipitate was 
vacuum-filtered and dried. The total yield of  
(BDMO-tBTSC) product was 
Figure 1: The reaction of  2,3-butanedione monoxime with 4-
tertbutyl-3-thiosemicarbazide to produce the title molecule, 
BDMO-tBTSC.
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1.264g (5.49 x 10-3 mol, 79.9% Yield).
3. A 50-mL Erlenmeyer flask containing a 
magnetic stir bar was placed within the hood, 
and 1.018 g (6.92 x 10-3 mol) of  4-tert-butyl-3-
thiosemicarbazide and 0.837g (7.019 x 10-3 
mol) of  2,3-butandione monoxime were added 
to the flask along with 25 mL of  a solution 
consisting of  50% ethanol and 50% of  5% 
acetic acid as solvent. The mixture was heated 
to 60oC and left to react overnight. The 
resulting white precipitate was vacuum-filtered 
and dried. The total yield of  (BDMO-tBTSC) 




N- Tertbutyl- 2- [2- (hydroxyimino) - 1- 
methylpropylidene] -hydrazinecarbothioamide. 
 
1H NMR (500 MHz, DMSO-d6) δ 11.64 (s, 
1H), 10.13 (s, 1H), 7.71 (s, 1H), 2.09 (s, 3H), 1.96 
(s, 3H), 1.51 (s, 9H). 
13C NMR (126 MHz, DMSO-d6) δ 176.21, 
154.00 , 146.19 , 52.64 , 28.39 , 11.75 , 9.12 . 
Results and Discussion
The reaction for the synthesis of  compound [1] 
BDMO-tBTSC is depicted in Figure 1, and our 
first synthesis procedure utilized isopropanol as 
the solvent and a catalytic amount of  sulfuric 
acid. The reaction was a success in that the 
product was formed, but the BDMO-tBTSC 
was so soluble in the isopropanol solvent that it 
wouldn’t precipitate out of  solution until the 
solvent was removed down to 5ml or less. In 
working with the compound and trying various 
solvents, we found that the compound was 
much less soluble in water, so we adjusted the 
reaction conditions by using a 50/50 mixture of  
ethanol and water with the catalytic amount of  
sulfuric acid. Simultaneously, we tried using a 
50/50 mixture of  ethanol and 5% acetic acid to 
do the same reaction. This synthesis attempt 
had the advantage of  using a weak acid (acetic 
acid) instead of  the strong acid (concentrated 
sulfuric acid). All three procedures produced the 
title compound, as shown by 1H NMR 
spectroscopy, but the third procedure gave the 
highest yield of  product.  
At TTU, we just received a National Science 
Foundation grant to purchase a new 500 MHz 
Bruker NMR spectrometer. This new state-of-
the-art instrument is capable of  NMR 
experimentation (such as 1H-15N HSQC) that 
we have never been able to do previously at 
TTU. This paper describes some of  that work 
in the following paragraphs.
The 1H NMR spectrum of  compound [1] is 
shown in Figure 2, and provides evidence for 
the structure of  the molecule. The 1H NMR 
spectrum shows peaks due to distinct proton 
signals, which correspond to particular 
hydrogen atoms in the compound. This gives us 
good evidence that we have not only made the 
compound, but we can also assign resonance 
peaks to every hydrogen atom in the 
compound.
Figure 2: The 1H NMR spectrum of  BDMO-tBTSC in 
DMSO-d6 solvent. (DMSO = dimethylsulfoxide) 
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The upfield protons in red (D, E, and F) are 
relatively easy to assign. The nine protons on 
the methyl groups on the tert-butyl group (F) 
appear as a singlet with an integration of  nine 
protons at 1.51 ppm. The three protons for 
either D or E are singlets with an integration of  
three protons each, at 2.09 ppm and 1.96 ppm 
respectively. The protons of  D, which are 
relatively close to the oxime group, are assigned 
to the more downfield peak at 2.09 ppm since 
they are in a more electronegative environment 
than the protons of  E. 
The downfield protons in blue (A, B, and C) are 
all singlets of  integration of  one proton each. 
Even though peak A looks bigger, it is actually 
much more narrow and sharp than B and C, 
which are relatively broader. 
The decoupled 13C NMR spectrum of  BDMO-
tBTSC in DMSO-d6 solvent is shown in Figure 
3. We have again labeled the carbon atoms of  
the molecule, this time with numbers, C1-C7, 
to designate their position in the molecular 
structure, and also their corresponding 
resonance in the NMR spectrum. The 
resonances were assignable to the 
corresponding carbon atoms, with the most 
downfield peak being assigned to the thione 
(C=S) carbon. 
The resonance peak assigned to the thioamide 
proton, labeled C in Figure 2, is consistent with 
this thioamide proton in several other 
compounds that we have previously published 
(9). However, the hydrazinic proton, labeled B 
in Figure 2, and the oxime proton, labeled A in 
Figure 2, are ambiguously assigned; we are not 
actually sure of  their assignment. They could 
be reversed. This is where we used a relatively 
new NMR experimental technique called 
HSQC to rid us of  the ambiguous assignments. 
Heteronuclear Single Quantum Coherence 
(HSQC) or Heteronuclear Single Quantum 
Correlation is a powerful experiment used in 
NMR spectroscopy of  organic molecules, and 
proteins. The experiment was first reported in 
the literature in 1980 by Bodenhausen and 
Ruben (10).  The resulting plot from this NMR 
experiment is two-dimensional (2D) with one 
axis for proton (1H) and the other for a 
heteronucleus (an atomic nucleus other than a 
proton), which is usually 13C or 15N; here we 
utilize the 15N nucleus. The spectrum contains a 
peak for each unique proton attached to the 
heteronucleus being considered, observed by 
their 1 bond 1H-15N coupling. So, this 
experiment allows us to “see” which proton is 
attached to which nitrogen atom in our 
BDMO-tBTSC molecule. 
In Figure 4, the 2d (1H-15N) HSQC plot is 
shown for the BDMO-tBTSC molecule. The 
ambiguously defined proton resonances at 
11.64 ppm and at 10.13 ppm can now be 
definitively assigned.  
In the X-axis 1H spectrum portion of  the 
HSQC plot in Figure 4, we see that the 
resonance at 11.64 ppm shows that that 
particular proton is not directly bound to a 
nitrogen atom because there is no respective 
Figure 3: The 13C NMR spectrum of  BDMO-tBTSC in 
DMSO-d6 solvent. The carbon atoms are labelled, and the 
large peak at ~40 ppm is the DMSO solvent.
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signal from the 15N nuclei in the molecule (the 
15N spectrum is on the Y-axis). However, we do 
see that the proton that resonates at 10.13 ppm 
is directly bound to a nitrogen atom in the 
molecule, because there is a corresponding 
signal at about 210 ppm from a 15N nucleus. It 
also shows that the thioamide proton peak at 
7.71 ppm has, as we already suspected, a 
corresponding signal from the nucleus of  the 
nitrogen atom it is bound to in the molecule, 
which resonates at 250 ppm.
 
Therefore, we can now unambiguously assign 
every proton to its corresponding resonance in 
the 1H NMR spectrum of  the BDMO-tBTSC 
molecule, as seen in Figure 2. 
With this work completed on the NMR 
characterization of  this new molecule, we hope 
to expand our research to include other 
chemical analogs of  the oxime-
thiosemicarbazone class of  molecules with the 
confidence that we can use our new 500 MHz 
instrument to characterize them. Once that is 
done we can proceed with testing of  their bio-
logical behaviors, and report our work in 
another peer-reviewed journal. 
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